Chemistry:Atagabalin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H19NO2 |
| Molar mass | 185.267 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It was under development as a treatment for insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.
See also
References
- ↑ "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters 20 (2): 461–4. January 2010. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.
- ↑ "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology 68 (2): 174–80. August 2009. doi:10.1111/j.1365-2125.2009.03444.x. PMID 19694735.
- ↑ "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research 1401: 1–9. May 2011. doi:10.1016/j.brainres.2011.05.025. PMID 21664606.
- ↑ "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research 28 (10): 2610–27. June 2011. doi:10.1007/s11095-011-0490-x. PMID 21681607.
 |  |
